ADVERTISEMENT

Comments?
Help us improve Portfolio Grader.


Comments?
Help us improve Portfolio Grader.


Blue Chip Growth

Stock Report: CTI BioPharma Corp. (CTIC) Report Updated: Oct 27, 2014 | Print This Page

Get more stock ratings by Louis Navellier

CTI BioPharma Corp. (CTIC)

Rating: Buy Volatility: Aggressive
Total Grade: B Industry: Biotechnology
Competitors: RGEN, MDXG, MACK, CBPO

Stock Analysis

Rating: Monthly View

A
B
C
D
F
October November December January February March April May June July August September

Rating: Weekly View

This Week: B down no change
Last Week: B same upgrade
Two Weeks Ago: C up downgrade
service keys

CTI BioPharma Corp.© quotemedia

Company Profile

Cell Therapeutics, Inc. engages in the development, acquisition, and commercialization of drugs for the treatment of cancer. It is developing Pixuvri, a novel anthracycline derivative for the treatment of hematologic malignancies and solid tumors; OPAXIO, a chemotherapeutic agent that links paclitaxel to a biodegradable polyglutamate for treating ovarian, brain, esophageal, head, and neck cancers; Brostallicin, a synthetic DNA minor groove binding agent; and Bisplatinates, a platinum-based chemotherapy drug to treat various cancers. The company, in collaboration with Chroma Therapeutics, Ltd., is also engaged in developing Tosedostat, an oral aminopeptidase inhibitor. Cell Therapeutics, Inc. was founded in 1991 and is headquartered in Seattle, Washington.

Recent News: CTI BioPharma Corp.